newsmaker

INFINOX Welcomes Isabella Mannucci as New Institutional Sales Hire to Strengthen LATAM Presence

INFINOX Appoints Isabella Mannucci as Institutional Sales – LatAm Introduction INFINOX, a global trading platform, has recently welcomed Isabella Mannucci to its team as the new Institutional Sales for Latin America. Mannucci’s appointment marks the third senior hire this year aimed at boosting the global growth of INFINOX’s IXO Prime division. Isabella Mannucci’s Role As…

Read More

Possible Securities Fraud Claims Against Bed Bath & Beyond Inc. Under Investigation by Wolf Haldenstein Adler Freeman & Herz LLP: What Shareholders Need to Know

Investigation Alert: Bed Bath & Beyond, Inc. Wolf Haldenstein Adler Freeman & Herz LLP Investigates Potential Securities Fraud Claims New York, Aug. 31, 2022 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP is currently investigating whether Bed Bath & Beyond, Inc. (“Bed Bath” or the “Company”) (NASDAQ: BBBY) complied with federal securities laws….

Read More

Breaking News: Exela Technologies Takes Europe by Storm with Exclusive XBP Platform!

Exela Technologies Signs Exclusive Non-Binding Letter of Intent to Create Stand-Alone European XBP Platform Setting the Stage for Innovation and Growth Did you hear the news? Exela Technologies, Inc. is making waves in the business process automation industry with their recent announcement of an exclusive non-binding letter of intent to create a stand-alone European XBP…

Read More

Finch Therapeutics Reclaims Full Control of Fin-524 and Fin-525: Promising Microbiome Products for IBD Development

Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Micro… SOMERVILLE, Mass., Aug. 25, 2022 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH) Finch Therapeutics, a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, has announced that it…

Read More